Director, Therapeutic Editing
AstraZeneca, Sweden
Pinar Akcakaya is a molecular biologists who received her PhD in 2015 at the Karolinska Institute, Stockholm, Sweden. Following that, she joined the AstraZeneca postdoctoral research program at Marcello Maresca`s team in Gothenburg, Sweden. As a postdoctoral scientist, Pinar worked on establishing novel tools to assess genome-wide precision of CRISPR‐Cas9 mediated gene engineering systems in vivo together with collaborators including Keith Joung, Jacob Corn and Stephen Ström. After completing her postdoctoral studies, she took a role as senior research scientist at AstraZeneca. Currently Pinar is working as Director at the Genome Engineering department at AstraZeneca, leading a team developing novel technologies towards generation of genome editing medicines. Pinar has received several awards in recognition of her work on developing CRISPR off-target evaluation approaches, including AstraZeneca CEO award for the best pre-clinical publication and IMED Science award for the postdoctoral scientist of the year.
Novel technologies for development of safer therapeutic genome editing medicines
Thursday, May 25, 2023
15:00 – 15:30 CET